Please provide your email address to receive an email when new articles are posted on . The 8-year long-term extension found no new safety signals with filgotinib for RA treatment. Disease response ...

In China, the real-world effectiveness and safety of Janus kinase 1 (JAK1) inhibitors for moderate-to-severe atopic dermatitis (AD) are of significant interest due to the approval of upadacitinib and ...

JAK inhibitors, a new class of tsDMARDs, have shown superior efficacy in RCTs for RA compared to other biologics. Real-world studies highlight JAK inhibitors' benefits in clinical disease activity, ...

Deuruxolitinib (12 mg twice daily) showed superior efficacy in achieving SALT20 and SALT10 scores compared to other treatments for alopecia areata. The study used a Bayesian network meta-analysis of ...

Previous, smaller studies had found that patients tended to gain weight while on the Janus kinase (JAK) inhibitor tofacitinib. This study, funded by tofacitinib's manufacturer, analyzed data from more ...

Favorable outcomes were observed among patients with vitiligo who received systemic Janus kinase inhibitors, with tofacitinib associated with the highest rate of complete resolution. Tofacitinib may ...

HealthDay News — For adults with severe alopecia areata (AA), ivarmacitinib, a selective Janus kinase 1 (JAK1) inhibitor, at doses of 4 and 8mg is efficacious and tolerable, according to a study ...

Recombinant zoster vaccine (RZV) had no significant effect on major adverse cardiovascular events; however, it reduced all-cause mortality in patients with immune-mediated inflammatory diseases ...

Please provide your email address to receive an email when new articles are posted on . WASHINGTON — Withholding Janus kinase or interleukin-17 inhibitors from patients with rheumatoid arthritis or ...

A 28-year-old woman presented to her primary care provider with the chief report of persistent itch associated with atopic dermatitis (AD), with itch severity worst on her hands bilaterally. AD was ...